The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 44 | — | 20.1x | Near average | |
Growth | 68 | 355.2% | 5.6% | Above average | |
Quality | 90 | 61.2% | 7.6% | Above average | |
Safety | 44 | -3.4x | 0.4x | Near average | |
Capital Return | 18 | — | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
BridgeBio Pharma, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy BridgeBio Pharma, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The analyst outlook for BBIO shows a state of cautious divergence; although the average price target remains stable at 105.21 dollars (representing a significant upside from the current price), recent movements indicate a slight decline in absolute optimism. This is evident in Raymond James' downgrade from 'Outperform' to 'Market Perform' and Citigroup's adoption of a 'Neutral' stance, reflecting increasing certainty regarding the current valuation versus operational risks.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.